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Introduction
This study was concerned with the
endovascular treatment of peripheral
arterial occlusive disease (PAOD) and
the techniques employed. Numerous
guidelines on this topic have already
been published. The version of the
S3 guidelines published in 2015 on the
diagnostics, therapy and follow-up care
of PAOD by the German Society for An-
giology – Society for Vascular Medicine
[1], suggests that when considering en-
dovascular treatment of medium to large
size femoropopliteal lesions, the primary
stent angioplasty with nitinol stents is
the preferred choice over balloon an-
gioplasty with secondary stent implants
(bail out stents). Conversely, when
considering treatment of infrapopliteal
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vessel lesions, a stent implant should
only be considered when balloon percu-
taneous transluminal angioplasty (PTA)
does not produce satisfactory angio-
graphic results. Although the value of
the new drug-eluting balloons in the an-
gioplasty of infrapopliteal arteries could
not be adequately assessed in the guide-
lines, drug-eluting (paclitaxel-coated)
balloons were, rather vaguely, deemed
useful in the endovascular treatment
of femoropopliteal lesions, particularly
when reduced risk of restenosis and
reintervention are considered clinically
essential (a goal that physicians in vas-
cular medicine should always strive for).
The new practice guidelines from the
Society for Vascular Surgery (SVS) [2]
recommend selective stenting of focal
lesions of the superﬁcial femoral artery
if PTA alone produces unsatisfactory re-
sults (bail out) and nitinol stenting (with
or without paclitaxel) for medium length
lesions. The importance of new tech-
niques in the clinical practice appears
to be unclear, as shown in a consensus
document from the Society for Cardio-
vascular Angiography and Interventions
(SCAI) [3]. The document calls for ad-
ditional data concerning the application
of drug-eluting balloons, drug-eluting
stents (DES), bioresorbable stents, cut-
ting balloons, cryoplasty, laser, rotary
and directional atherectomy, before wide
propagation can begin particularly with
regard to cost eﬀectiveness.
The variety of the techniques listed
here prompted us to raise the question
of the frequency in which German vas-
cular surgeons, radiologists and angiolo-
gists currently apply thesemethods in the
endovascular treatment of infrainguinal
PAOD. Here, a further distinction be-
tween femoropopliteal and infrapopliteal
lesions was made. The current study is
to serve as a form of inventory so that
treatment trends and developments can
be assessed following future repeat and
follow-up investigations.
Patients andmethods
This was a prospective, non-random-
ized, multicentric study design. The
percutaneous infrainguinal stent (PSI)
registry study included all percutaneous
endovascular treatment in patients with
infrainguinal PAOD from 1 September
2015 to 30 November 2015 (91 days)
across 79 participating German centers.
A total of 200 centers (all levels of care)
were asked to participate in the study,
while vascular surgeonswere theprimary
points of contact. If it was revealed that
such procedures were not performed on
the patient wards of the departments,
other neighboring departments were
contacted. Willingness to participate
in the study was 40%. Patients with
intermittent claudication (IC, Fontaine
stage II) or critical limb ischemia (CLI,
Fontaine stages III or IV) were included.
Each intervention performed was docu-
mented as an individual treatment case,
so that patients could be included multi-
ple times if interventions were repeated.
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Table 1 Reported variables for endovas-
cular therapy of patients with infrainguinal
























Discharge goal(s) 2716 97.1
Data collection and anonymous sub-
mission to the trial center were carried
out by the participating centers. Trial
centers with less than 5 treatment cases
reported within the 3-month trial pe-
riod or centers that could not ensure
the submission of all treated patients
were excluded from participation. In
total, 10 reported treatment cases were
excluded.
Based on the fact that the PSI study
data consisted of anonymized treatment
data from routine operations, which did
not allow patient identiﬁcation, themed-
ical council ethics committees of both
Hamburg and Düsseldorf found that the
study was not within their consulting ju-
risdiction and therefore posed no objec-
tions to the planned studies. The statis-
tical analysis of the data was performed
with SPSS version 22.0 (Armonk, NY).
A group comparison with respect to the
metric variables was done with Student’s
t-test (for normally distributed variables)
or with the Mann-Whitney U-test (for
non-normally distributed variables). For
categorical variables, Fisher’s exact test
or the χ2-test was employed. The signif-
icance level was chosen to be p < 0.05.
Because it was not possible to perform
aplausibility check for data in paper form
and because obligatory data were not al-
ways reported in their entirety, only valid
data (valid percentages) were used in the
calculations. As a result, the population
size diﬀered among the selected variables
(. Table 1). This has been noted in the
individual collectives.
Results
Participating centers and specialist
disciplines
A total of 79 centers were eligible for the
PSIregisterstudybycommittingtoreport
data fromall treatment cases. Cases from
5 centers could not be included as either
the minimum of 5 cases in 3 months was
not achieved or the complete submission
of data could not be conﬁrmed or val-
idated. A total of 2798 cases received
from 74 trial centers were included in
the ﬁnal analysis (. Fig. 1). On average,
38 cases per center (range 5–161) were
documented. According to the informa-
tion on the website, 65 of the 74 partic-
ipating centers (87.8 %) were headed by
a vascular surgeon (ward with patient
beds), the remainder were distributed
among departments under mixed lead-
ership (n = 2), radiology (n = 2) and
angiology (n = 5). The primary disci-
pline of medical personnel who carried
out the interventions was indicated to
be 1517 out of 2626 (57.8 %) in vascu-
lar surgery, 794 (30.2 %) in radiology and
307 (11.7 %) in angiology. On the patient
wards in the vascular surgery depart-
ments 60.1 % of the interventions were
performed by vascular surgeons them-
selves, 32.8 % by radiologists and 6.9 %
by angiologists.
Patient collective
In 2761 out of 2798 treatment cases, in-
formation regarding patient sex was pro-
vided. A total of 1696 (61.4 %) men
and 1065 (38.6 %) women were enrolled
in this study. The average age of the
male patients was 70.4 years (SD 10.0,
median 71 years). The treated women
were with an average age of 75.8 years
(SD 10.5, median 77 years) signiﬁcantly
older (p < 0.001). The frequency of treat-
ment for the right and left lower limbs
(52.2 % vs. 47.8 %, respectively) did not
signiﬁcantly diﬀer. Out of 2704 treat-
ment cases 1798 (66.5 %) were primary
operations, whereas in 906 of the cases
(33.5 %) patients had also been previ-
ously treated. Comorbidities and risk
factors of patients, grouped according to
gender are listed in . Table 2. Almost
50% of the men and 39.3 % of women
also suﬀered from diabetes mellitus. Se-
vere chronic renal failure stage 4 and 5
with a glomerular ﬁltration rate (GFR)
<30 ml/min was indicated in 11.2 % of
men and 12.6 % of women and 4.4% of
men and 3.5% of women were dialysis-
dependent. Furthermore, there were sig-
niﬁcantlymoreactive smokersamongthe
men (30.8 % vs. 20.6 % of the women).
. Table 3 provides an overview of the
risk factors in patients with IC and CLI.
Patients with CLI suﬀered signiﬁcantly
more frequently from atrial ﬁbrillation
(22.8 % vs. 8.0 %, p < 0.001), diabetes
mellitus (57.1 %vs. 31.8 %, p<0.001)and
chronic kidney disease (17.6 % vs. 5.0%,
p< 0.001) andweremore frequently dial-
ysis-dependent, when compared to pa-
tients with IC. In addition, patients suf-
fering fromCLI were on average 75 years
of age and therefore signiﬁcantly older
thanpatientswith IC(average69.4years).
Treatment indications and outﬂow
prior to intervention
Treatment indications and outﬂow prior
to intervention are listed in . Fig. 2. The
majority of the procedures carried out
(1259 out of 2754 or 45.7 %) were due
to PAOD stage II (intermittent clau-
dication), followed by PAOD stage IV
(1175 or 42.7 %) and stage III (320 or
11.6 %). Patency of 3 crural vessels was
observed in 41.3 %, 21.6 % and 10.8 % of
the stage II, III and IV treatment cases,
respectively.
Anesthesia
The operation was performed with the
patient under local anesthesia in 2284
(83.0 %) of the cases.
Procedural approach and closure
In 1796 (64.2 %) of the procedures ac-
cess was achieved via inguinal antegrade
puncture, while 889 (31.8 %) cases were
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Percutaneous endovascular treatment of infrainguinal PAOD. Results of the PSI register study in
74 German vascular centers
Abstract
Background. The percutaneous infrainguinal
stent (PSI) register study aimed to collate
all percutaneous endovascular procedures
for infrainguinal peripheral arterial occlusive
disease (PAOD) conducted in 74 German
vascular centers between September and
November 2015 (3 months). In order to
obtain representative results all consecutive
treatment procedures had to be submitted by
the participating trial centers.
Material and methods. This was a pro-
spective, nonrandomized multicenter study
design. All patients suﬀering from intermittent
claudication (IC, Fontaine stage II) or critical
limb ischemia (CLI, Fontaine stages III and IV)
were included. Trial centers with less than
5 cases reported within the 3-month trial
period or centers that could not ensure
the submission of all treated patients were
excluded.
Results. In the ﬁnal assessment 2798 treated
cases from 74 trial centers were reported of
which 65 (87.8 %) centers were under the
leadership of a vascular surgeon. Approxi-
mately 33% of the interventions in centers
under the leadership of vascular surgeons
were conducted by radiologists. Risk factors,
especially chronic renal disease, diabetes
and cardiac risk factors were signiﬁcantly
diﬀerent between patients with IC and CLI.
Of the patients with Fontaine stage II PAOD
41.3% had 3 patent crural vessels compared
to only 10.8 % of patients with Fontaine
stage IV. With respect to peri-interventional
complications, percutaneous endovascular
treatment of IC was a safe procedure with
severe complications in less than 1 % and no
fatalities. Only 4.5 % of the procedures were
conducted under ambulatory conditions.
In the supragenual region self-expanding
bare metal stents, standard percutaneous
transluminal angioplasty (PTA) and drug-
coated balloons were the most frequently
used procedures. For interventions below the
knee, standard PTA was the most commonly
employed treatment.
Conclusion. The main aim of the PSI study was
to obtain a realistic picture of percutaneous
endovascular techniques used to treat
suprapopliteal and infrapopliteal PAOD lesions
and to describe the treatment procedures
used by vascular specialists in Germany. To
investigate the change in trends for treatment
over time, this study has to be repeated in the
future in order to test how quickly the results
of randomized studies can be implemented in
practice.
Keywords
Percutaneous infrainguinal stent · Peripheral
arterial occlusive disease · Endovascular ·
Percutaneous · GermanVasc





einen Zeitraum von 3 Monaten an einer
möglichst repräsentativen Zahl von mehr-
heitlich gefäßchirurgischen Gefäßzentren
konsekutiv alle perkutanen endovaskulären
Behandlungen bei infrainguinaler peripherer
arterieller Verschlusskrankheit (PAVK)
erfassen und dadurch einen Einblick in die
Versorgungsrealität ermöglichen.
Material und Methode. Es handelte sich
um eine prospektive, nichtrandomisierte
Multizenterstudie. Eingeschlossen wurden
Patienten mit einer intermittierenden
Claudicatio (IC, Fontaine-Stadium II) und
einer kritischen Extremitätenischämie (CLI,
Fontaine-Stadien III und IV). Zentren mit einer
Datenübermittlungvon weniger als 5 Behand-
lungsfällen in 3Monatenoder nichtbestätigter
konsekutiver Datenübermittlungwurden von
der Teilnahme ausgeschlossen.
Ergebnisse. In die Endauswertung gingen
insgesamt 2798 Behandlungsfälle aus
74 Studienzentren ein. Von den 74 Zentren
standen 65 (87,8 %) unter gefäßchirurgischer
Leitung. Etwa 33% der Interventionen in
gefäßchirurgisch geführten Zentren wurden
durch Radiologen durchgeführt. Patienten
mit IC und CLI unterschieden sich signiﬁkant
in ihren Risikofaktoren, wobei besonders
chronische Nierenerkrankungen, Diabetes
mellitus und kardiale Risikofaktoren zu
betonen sind. Es wiesen 41,3 % der Patienten
mit PAVK im Fontaine-Stadium IIi 3 oﬀene
Unterschenkelgefäße auf, verglichen mit
lediglich 10,8% der Patienten im Fontaine-
Stadium IV. Die perkutane endovaskuläre
Behandlung der IC war hinsichtlich schwerer
periinterventioneller Komplikationen ein
sicheres Verfahren, schwere Komplikationen
traten in weniger als 1 % auf, keine Todesfälle
bei IC. Nur 4,5 % aller Behandlungen wurden
unter ambulanten Bedingungen durchge-
führt. In der suprapoplitealen Strombahn
wurde der selbstexpandierende „bare metal
stent“ vor dem Standard-verfahren der
perkutanen transluminalen Angioplastie
(PTA) und demmedikamentenbeschichteten
Ballon am häuﬁgsten verwendet. In der
infrapoplitealen Strombahn fand die
Standard-PTA den häuﬁgsten Zuspruch.
Schlussfolgerung. Wesentliche Aufgabe der
PSI-Register-Studie war es, die angewandten
endovaskulären Techniken bei supra- und
infrapoplitealen Läsionen zu erfassen sowie
Daten für eine Beschreibung der Istsituation
zu erheben. Dies soll es in Zukunft – bei
Wiederholung der Untersuchung – ermögli-
chen, Behandlungstrends nachzuweisen, um
überprüfen zu können, wie schnell sich die
Ergebnisse (randomisierter) Studien in der
Praxis umsetzen lassen.
Schlüsselwörter
PSI · PAVK · Endovaskulär · Perkutan ·
GermanVasc
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Fig. 18 Reporteddata fromtheparticipatingtrialcentersasnameofthechief investigator(s) (average
38 cases per center)
performed using an inguinal retro-
grade approach (crossover). A brachial
and popliteal vascular approach was
performed in only 26 and 6 cases, re-
spectively. Inguinal antegrade puncture
was the most frequently selected access
in both vascular surgical and radiolog-
ical interventions (64.0 % and 82.6%,
respectively). Angiology interventions
were preferred over the inguinal retro-
grade crossover approach, being per-
formed in 61.1 % of the cases. When
deciding which method was best to use
in the treatment of vascular puncture
site, simple compression bandages as
well as a variety of common closure
devices were also investigated. Com-
pression bandages were most frequently
applied in 43.6 % of cases. Second and
third places were AngioSeal (24.9 %)
and ExoSeal (11.8 %), respectively. The
technique of vessel closure by FemoStop
was almost exclusively employed by
vascular surgeons. An overview of the
distribution of the various methods for
the treatment of vascular puncture site
is provided in . Table 4.
Treated vessel, procedures and
devices
Data concerning the treated ﬂow path
were reported in 2701 cases (. Fig. 3).
The suprapopliteal ﬂow path, down
to and including the P2 segment was
treated in 59.5 % of the patient cases, in-
frapopliteal vessels in 18.8 %. In 21.7 %
of the cases, treatment of both sec-
tions was indicated. For stage II cases,
the suprapopliteal and infrapopliteal
ﬂow areas were aﬀected in 84.9 % and
4.9%, respectively (10.3 % both). In
patients suﬀering from CLI 38.7 % of
the cases involved the suprapopliteal
artery and 30.1 % the infrapopliteal
(31.2 % both).Of the suprapopliteal in-
terventions 722 were conducted using
standard PTA (uncoated balloon PTA),
while 665 employed drug-coated bal-
loons and 748 nitinol bare metal stents.
Only 48 of the implanted or employed
suprapopliteal devices were covered
stents. In the infrapopliteal segment
(below P3) 743 procedures (i. e. the
great majority) were performed exclu-
sively using standard PTA. Only 153 of
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Table 2 Distribution of risk factors of 2761 treatment cases separated according to sex
Risk factor Men Women p-Value
n = 1696 n = 1065
Age (years, median) 70.39 (71) 75.81 (77) <0.001
Active smoker status 522/1696 (30.8 %) 219/1065 (20.6 %) <0.001
Coronary heart disease 660/1696 (38.9 %) 353/1065 (33.1 %) 0.002
Acute coronary syndrome
(in the previous 6 months)
47/1696 (2.8 %) 18/1065 (1.7 %) n. s.
Atrial ﬁbrillation 255/1696 (15.0 %) 190/1065 (17.8 %) n. s.
Obesity (BMI >30 kg/m2) 197/1696 (11.6 %) 140/1065 (13.1 %) n. s.
Diabetesmellitus 838/1696 (49.4 %) 419/1065 (39.3 %) <0.001
Chronic renal disease
(stage 4/GFR <30ml/min)
190/1696 (11.2 %) 134/1065 (12.6 %) n. s.
Dialysis dependency 74/1696 (4.4 %) 37/1065 (3.5 %) n. s.
Stroke or TIA
(in the previous 6 months)
24/1696 (1.4 %) 10/1065 (0.9 %) n. s.
BMIbodymass index,GFRglomerular filtration rate, TIA transient ischemic attack,n.s. not significant






n = 1259 n = 1495
Men n (%) 782/1240 (63.1 %) 885/1477 (59.9 %) n. s.
Age (years, median) 69.43 (70) 75.00 (76) <0.001
Active smoker status 482/1259 (38.3 %) 264/1495 (17.7 %) <0.001
Coronary heart disease 409/1259 (32.5 %) 602/1495 (40.3 %) <0.001
Acute coronary syndrome
(in the previous 6 months)
25/1259 (2.0 %) 40/1495 (2.7 %) n. s.
Atrial ﬁbrillation 101/1259 (8.0 %) 341/1495 (22.8 %) <0.001
Obesity (BMI >30 kg/m2) 136/1259 (10.8 %) 207/1495 (13.8 %) 0.016
Diabetesmellitus 400/1259 (31.8 %) 853/1495 (57.1 %) <0.001
Chronic renal disease
(stage 4 and 5/GFR <30ml/min)
63/1259 (5.0 %) 263/1495 (17.6 %) <0.001
Dialysis dependency 14/1259 (1.1 %) 96/1495 (6.4 %) <0.001
Stroke or TIA
(in the previous 6 months)
15/1259 (1.2 %) 18/1495 (1.2 %) n. s.
BMIbodymass index,GFRglomerular filtration rate, TIA transient ischemic attack,n.s. not significant
the devices used were coated balloons.
Uncoated self-expanding stents were
implanted in 60 cases.
Anticoagulationmedication
Information concerning anticoagulation
therapy (both before and after inter-
ventions) can be found in . Table 5.
A distinction was made between the
two antiplatelet drugs acetylsalicylic
acid (ASA) and clopidogrel and speciﬁc
anticoagulants. In addition to vitamin
K antagonists (VKA, e. g. warfarin), so-
called new oral anticoagulants (NOAC),
e. g. Xarelto® (rivaroxaban) or Pradaxa®
(dabigatran) were also registered. Of
the patients 9.5 % (n = 267) were not
taking any anticoagulation medication
prior to the intervention, which rose
to 11.3 % (n = 317) postintervention.
Approximately 65.0 % of patients were
taking ASA as home medication, while
3.3% were under clopidogrel therapy.
10.3% of patients received dual platelet
inhibition with ASA and clopidogrel
prior to treatment, increasing to 50.4 %
following interventions (. Table 5). Of
the patients with atrial ﬁbrillation 23.2 %
(n = 104) had no a VKA, NOAC or hep-
arin as part of the medication regime
prior to treatment. Following treatment,
42.3 % received a VKA, while 22.9 and




When evaluating the intraoperative and
postoperative complications, a distinc-
tion was made between patients with IC
and CLI.The groups did not diﬀer in the
number of intraoperative complications
(. Table 6) and postoperative complica-
tions as listed in. Table 7 and 8. None of
thepatients suﬀering fromICdiedduring
the hospital stay, in contrast to 19 (1.3 %)
patients with CLI. It was not possible to
determine the stage of PAOD in any of
the deceased patients; however, it was
determined that such patients had sig-
niﬁcantly more risk factors than those
who survived (. Table 9). In particu-
lar, the proportions of atrial ﬁbrillation
(45.0 % vs. 16.0 %, p = 0.002), chronic
kidney disease (35.0 % vs. 11.7 %, p =
0.006) and dialysis-dependency (10.0 %
vs. 4.0%, p = 0.190) were signiﬁcantly
higher in the deceased patient group.
Length of hospital stay
The length of stay (LOS) based on a to-
tal of 2696 valid data, was 7.8 days
(median 4, minimum 0–maximum 280).
Before intervention, the average LOSwas
2.9 days (median 1, minimum 0–maxi-
mum 274) and postintervention 5.0 days
(median 2, minimum 0–maximum 75).
Average LOS for the individual stages
of PAOD is presented in . Fig. 4. It was
found that the duration of hospitaliza-
tion correlated with the severity or stage
of PAOD. Patients with PAOD stage IV,
for example, remained in hospital an
average of 4.8 days (median 2, mini-
mum 0–maximum 260) before interven-
tion and a further 8.0 days (median 5,
minimum 0–maximum 75) following
treatment. Patients with PAOD stage II,
however, only remained an average of
1.1 days (median 0, minimum 0–max-
imum 153) and 2.2 days (median 1,
minimum 0–maximum 64) pretreat-
ment and posttreatment, respectively.
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Fig. 28 Distribution of treatment indications and outﬂowprior to intervention, grouped according
to indications (PAODperipheral arterial occlusive disease, Fontaine stage)
120 (4.5 %) patients remained in hos-
pital for less than 1 day, 90 (76.3 %) of
whichhad ICand28 (23.7%)CLI.For the
2 remaining cases, staging was not pos-
sible. 482 (17.9 %) patients remained in
hospital overnight, 7.3 % of patients suf-
fering fromand treated for PAODstage II
were discharged on the day of treatment,
while 31.9 % remained overnight. The
rates of discharge for patients treated for
PAOD stages III and IV were 2.0 % and
5.4%, respectively.
Discharge destinations and results
Patency rate was used to gauge treat-
ment result at the time of discharge,
although no particular method for in-
vestigation was speciﬁed. It was shown
that 58 (2.1 %) of the treated patients
had closed reconstructions (1.9 % with
IC, 2.4 % with CLI, 1.7 % following
suprapopliteal reconstruction, 3.3 % fol-
lowing infrapopliteal reconstruction
3.3 % and 2.6% following multiple level
reconstruction). In 2432 (86.9 %) of the
patients the reconstruction status was
determined to be open or patent at the
time of discharge. For the remaining
308 cases (11.0 %) the revascularization
status could not be determined. On
investigation of discharge destinations, a
diﬀerentiation was made between trans-
fer to another hospital, discharge to
home or discharge to a nursing facility.
Overall 83.8 % of the patients were able
to return home following treatment,
while 9.7 % (273) were either sent to
a nursing home (5.3 %) or transferred
to another hospital (4.4 %). A total of
20 patients (0.7 %) died during hospital-
ization. While 96.0 % of the patients with
IC could be discharged to home only
74.1% of patients suﬀering from CLI
could return to private residences and
9.4% of the latter group were transferred




endovascular practices and interventions
forbothsuprapopliteal and infrapopliteal
lesions in patients with IC andCLI, using
data from the greatest possible number
of patients from predominantly vascular
surgery departments as well as cooperat-
ing radiology or angiology departments.
Of the contacted 200 vascular centers,
79 (40%) were willing to participate. In
a consecutive 3-month observation pe-
riod, 2798 treatment cases could be in-
cluded. This consecutive time frame was
chosen in order to avoid any patient se-
lectionbias. Only the74centers thatwere
able to ensure a continuous acquisition
of patient data from the target popu-
lation were included in the evaluation.
The limited 3-month survey period was
also selected to minimize the amount
of additional (non-remunerated) docu-
mentation work required from the par-
ticipatinghospitals. As itwasnotpossible
to monitor all of the trial centers, some
of the information provided was incom-
plete and as a result the included popu-
lation sizes diﬀered somewhat between
each variable. This aspect is indicated
where relevant. The representativeness
of the present study for the target popu-
lation of all treated patients in Germany
therefore remains to be determined, par-
ticularly as such a survey, as with all vol-
unteer register surveys, depends on the
number of centers willing to participate
and take on the additional task of extra
documentation. A limitation to the re-
sults of this study was due to the fact that
primarily vascular surgery departments
were involved. Furthermore, investiga-
tion of events following discharge (i. e.
long-term clinical outcomes) were not
the subject of the current investigation.
The complications and events associated
with the treatment described here are
therefore limited to the period of hospi-
talization.
In 2009 Malyar et al. [4] described
50,180 endovascular revascularization
procedures in patients in Germany with
PAOD Fontaine stage IIB, 11,704 in
patients with resting pain and 30,407 en-
dovascular revascularizations in patients
with CLI, all of which were inpatient
procedures. Accordingly, endovascular
interventions for patients suﬀering from
IC representedmore than half of all such
treatment performed inGermany for this
time period. In the patient population
of the current study the proportion of
patients with IC (45.7 %) was also very
high, a fact which appears to conﬂict
with guideline recommendations, which
are more reserved when it comes to
revascularization procedures of patients
with IC. The German S3 guidelines
state the following [1]: in patients suf-
fering from intermittent claudication,
supervised exercise programs aimed at
increasing walking distance are similarly
as eﬀective as endovascular or vascular
surgery interventions (recommendation
grade A, evidence grade 1). In a system-
atic review, monitored walking exercise
and PTA were also found to be equally
eﬀective [5]. Despite this, the use of
monitored walking exercise as treatment
S22 Gefässchirurgie · Suppl 1 · 2017
Table 4 Choice of closure system according to treating specialist discipline
Total Vascular surgery Radiology Angiology Other
n = 2774 n = 1499 n = 790 n = 305 n = 8
Compression
Bandage
1210 (43.6 %) 583 (38.9 %) 452 (57.2 %) 101 (33.1 %) 2 (25%)
AngioSeal (S. Jude Medical GmbH, Eschborn, Germany) 692 (24.9 %) 337 (22.5 %) 150 (19.0 %) 147 (48.2 %) 1 (12.5 %)
ExoSeal (Cordis, Baar, Switzerland) 328 (11.8 %) 121 (8.1 %) 157 (19.9 %) 33 (10.8 %) 0
StarClose (Abbott Vascular, Santa Clara, USA) 235 (8.5 %) 193 (12.9 %) 18 (2.3 %) 3 (1.0 %) 5 (62.5 %)
FemoStop (St. Jude Medical, Eschborn, Germany) 124 (4.5 %) 121 (8.1 %) 1 (0.1 %) 1 (0.3 %) 0
PerClose (Abbott Vascular, Santa Clara, USA) 10(0.4 %) 7(0.5 %) 3(0.4 %) 0 0
Other 175 (6.3 %) 137 (9.1 %) 9 (1.1 %) 20 (6.6 %) 0
Table 5 Anticoagulationmedication of treated patients prior to and following interventions
(italic antiplatelet therapy)
n = 2798 Treatment cases Medication
Prior to intervention On discharge
No anticoagulationmedication 267 (9.5 %) 317 (11.3 %)
No antiplatelet therapy 609 (21.8 %) 463 (16.5 %)
ASA only (without clopidogrel) 1818 (65%) 743 (26.6%)
Clopidogrel only (without ASA) 83 (3.0 %) 181 (6.5 %)
ASA and clopidogrel (dual) 288 (10.3%) 1411 (50.4%)
Vitamin K antagonists (e. g. warfarin) 289 (10.3 %) 216 (7.7 %)
New oral anticoagulants (NOAC, e. g. rivaroxaban) 162 (5.8 %) 153 (5.5 %)
Heparin (LMWH) 448 (16.0 %) 317 (11.3 %)
Other (e. g. abciximab) 34 (1.2 %) 32 (1.1 %)
ASA acetylsalicylic acid, LMWH low molecular weight heparin
Table 6 Distribution of complications during procedures according to treatment indications.
Distributionaccordingtotreatment indication (intermittentclaudicationvs.critical limb ischemia)
Intermittent claudication (n = 1259) Critical limb ischemia (n = 1495)
Dissection 59/1259 (4.7 %) 45/1495 (3.0 %)
Embolism 23/1259 (1.8 %) 29/1495 (1.9 %)
Perforation 5/1259 (0.4 %) 10/1495 (0.7 %)
Other 11/1259 (0.9 %) 16/1495 (1.1 %)
has not been enforced and endovascu-
lar procedures remain the established
practice for the treatment of IC. This
was further demonstrated in the large
nationwide inpatient sample (NIS) sur-
vey database (1999–2007) performed by
Sachs et al. [6]. Here, 128,937 patients
with IC received PTA +/- stent, while
only 89,776 CLI patients received the
same (all endovascular interventions in-
cluding thosewhichwere suprainguinal);
therefore, IC is not a less frequent in-
dication for endovascular procedures
compared to CLI.
In the PSI study patients suﬀering
from CLI were both older and more
severely ill than patients with IC. Di-
abetes mellitus, chronic kidney disease
and coronary heart disease were all sig-
niﬁcantly more frequent in patients with
CLI. Run-oﬀwas also signiﬁcantlyworse.
Similar observations were also made by
other authors [7, 8]. In the NIS (USA)
database the proportion of diabetic pa-
tients with CLI was almost twice as high
as those with IC, while the proportion
of patients with reduced renal function
was almost three times higher [9]. In
accordance with the less favorable ini-
tial conditions, postoperativedeathswere
only documented for patients with CLI
in the PSI study; however, the details of
the postoperative complications should
be interpreted with caution as should the
lowhospitalmortality of 1.3 % inpatients
suﬀeringfromCLI.Due toorganizational
limitations in the PSI study patients were
only observed up until the time of dis-
charge from the hospital. Accordingly,
hospital mortality was determined and
not the standard 30-day mortality. Sachs
et al. [6] were also only able to deter-
minehospitalmortality: 0.2 %ofpatients
who received endovascular treatment for
IC and 2.1% of those who received the
same for CLI. In the present study, the
patency rate at discharge was also re-
markably low. Only 2.1 % of patients had
occluded revascularizations at the timeof
discharge. Itmustbenoted, however, that
in 11% of cases patency of reconstruc-
tion was not documented at discharge;
the results are therefore not valid and
shouldbecritically interpreted. Inanear-
lier pilot study concerning endovascular
treatment of IC and CLI, patency rates of
91.9 and 94.6 % were observed, respec-
tively [10]. In the CRITISCH study, all
formsofhemodynamic failure (including
major amputations) following endovas-
cular treatment were documented in pa-
tients with CLI and were observed at a
total of 13% [11].
It is important to stress that thepresent
survey only secondarily serves as an out-
come study in which the results of en-
dovascular treatment of both IC and CLI
were compared over a short time period.
Theprimaryobjectivewasmore to inven-
tory current practices and techniques in
the percutaneous endovascular therapy
of infrainguinal PAOD in various depart-
ments, predominantly vascular surgery,
as apilot study(with theabovementioned
restrictions). Data concerning this topic
are completely lacking inGermany. Until
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this point, only estimated survey results
have been published. For example, in
a survey from Schmitz-Rixen et al. [12]
171 out of 223 (76.7 %) senior vascular
surgeons described their departments as
being a stand-alonedepartmentof vascu-
lar surgery, while 47 (21.1 %) were said
to be a subdivision of general surgery
and 5 (2.2 %) a subdivision of the car-
diac surgerydepartment. Theproportion
of radiology departments responsible for
percutaneous arterial interventions was
estimated to be 51–75 % from 16.7%
of survey respondents, to 76–99% from
27.4% and 100% from 15.5% of respon-
dents whereas14.5 % reported that none
ofthe interventionswereperformedasra-
diology procedures. Regarding vascular
surgery, 8.3 % estimated the proportion
of percutaneous arterial interventions to
be 76–99%, while 23.3% estimated it
to be 100%. 8.2 % reported that, in the
vascularsurgerydepartment, nopercuta-
neous arterial interventions were carried
out, while 40.9 % guessed the proportion
of vascular surgery performing percuta-
neous interventions to be between 1 and
25%. These estimations were further re-
ﬁned in the PSI study. In the vascular
surgery departments, 60.1 % of percuta-
neous interventions were performed by
vascular surgeons themselves, 32.8 % by
radiologists and 6.9 % by angiologists.
It was also possible to distinguish be-
tween individual preferences and habits.
This concerned, among other things, the
choice of inguinal approach/access, the
majority of vascular surgeons preferred
an inguinal antegrade approach. This
technique is not often employed by an-
giologists; this group rather appears to
prefer the inguinal retrograde crossover
approach, which was selected in 61.1 %
of cases. There were also signiﬁcant dif-
ferences in the choice of closure system,
as shown in . Table 4.
One point all guidelines agree on is
postoperative antiplatelet therapy. In
the German guidelines [1] the following
is recommended: all patients should
receive 100 mg ASA before, during and
after interventions. Treatment should be
continued for the long term, provided
there are no contraindications (level of
recommendation A, evidence level 1).
Still under discussion is the option of
a combination therapy with clopidogrel.
In this case, theguidelines statemore cau-
tiously caution: following infrainguinal
endovascular therapy with stenting, the
temporary combination of ASA and
clopidogrel can be recommended to
improve the patency rate. Because the
present studydemonstrated that in a con-
siderable proportion of cases (16.5 %)
no postoperative antiplatelet therapy was
documented, further clariﬁcation is ur-
gently required in other cohort studies.
Conversely, 5.5 % of patients were sup-
plied with NOAC and 7.7%with vitamin
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MACE 1/1259 (0.1 %) 28/1495 (1.9 %)
Myocardial infarction 1/1259 (0.1 %) 8/1495 (0.5 %)
Stroke/TIA 0/1259 (0 %) 1/1495 (0.1 %)
Death (following discharge) 0/1259 (0 %) 19/1495 (1.3 %)
MACEmajor adverse cardiac events, TIA transient ischemic attack
Table 8 Distribution of other complications following interventions excludingmajor adverse
cardiovascular events (MACE) according to treatment indications.Distribution according to treat-





Pulmonary complications 2/1259 (0.2 %) 17/1495 (1.1 %)
Pseudoaneurysm 14/1259 (1.1 %) 18/1495 (1.2 %)
Compartment syndrome 1/1259 (0.1 %) 4/1495 (0.3 %)
Reintervention (endovascular) 6/1259 (0.5 %) 16/1495 (1.1 %)
Reintervention (surgical) 4/1259 (0.3 %) 29/1495 (1.9 %)
Major amputation (unplanned) 0/1259 (0%) 14/1495 (0.9 %)
Minor amputation (unplanned) 0/1259 (0%) 13/1495 (0.9 %)
Hemorrhage (requiring revision) 10/1259 (0.8 %) 14/1495 (0.9 %)
Wound infections 1/1259 (0.1 %) 14/1495 (0.9 %)
Table 9 Risk factors andepidemiologicaldataof fatalities in treatment cases comparedwith the
total study population
Fatalities Total study population
n = 20 n = 2798
Proportion of men/women (%) 14/6 (70/30%) 1696/1065 (60.6/39.4%)
Age (average, years median) 80.05 (79) 72.46 (74)
Proportion of primary interventions 12 (60.0 %) 1798/2704 (66.5 %)
Coronary heart disease 9 (45.0 %) 1025/2798 (36.6 %)
Acute coronary syndrome (in the previous
6 months)
1 (5.0 %) 67/2798 (2.4 %)
Atrial ﬁbrillation 9 (45.0 %) 449/2798 (16.0 %)
Diabetesmellitus 11 (55.0 %) 1271/2798 (45.4 %)
Chronic renal disease
(stage 4/GFR <30ml/min)
7 (35.0 %) 327/2798 (11.7 %)
Dialysis dependency 2 (10.0 %) 112/2798 (4.0 %)
Stroke or TIA (in the previous 6 months) 0 (0 %) 34/2798 (1.2 %)
GFR glomerular filtration rate, TIA transient ischemic attack
K antagonists, in apparent contrast to
guideline recommendations (evidence
level 1): oral anticoagulants are not to
be used after PTA of femoropopliteal or
tibial lesions; however, 8 % of patients
with IC and 22.8 % of patients with
CLI also suﬀered from atrial ﬁbrillation.
Whether this suﬃces as an indication
for anticoagulation could not be deter-
mined, although it should be noted that
relatively few patients with atrial ﬁbril-
lation received treatment with NOACs
or vitamin K antagonists.
From theNIS database, Sachs et al. [6]
found the average length of hospital stay
in patients receiving PTA +/- stent to be
1.0 +/- 0.02 days, although 87.8 % of the
procedures were performed as same day
surgery. Lo et al. [13] also used the NIS
database. In their study, they reported
over 230,469 endovascular procedures in
patients with IC between 1998 and 2009.
In 2009, 65% of interventions in men
and 61% in women were performed as
outpatient procedures. In CLI, however,
they observed that inpatient endovascu-
lar procedures were performed 2.7 times
more often than outpatient procedures.
In comparison to these studies, the aver-
age length of hospital stay in the patient
population of the present study is rela-
tively long. Only 4.5 % of all treatments
were carried out as outpatient or same
day surgery procedures, although a dis-
tinct diﬀerence could be observed be-
tween patients with PAOD II and those
with PAOD III/IV. For example, 7.3 % of
patients treated for PAOD stage II were
discharged on the day of treatment, while
31.9 % stayed overnight in hospital. In
patients with PAOD III and IV the num-
bers were 2.0 and 5.4 %, respectively.
The analysis of the selected tech-
niques used to treat suprapopliteal
and infrapopliteal lesions proved to
be an important point of investigation.
Suprapopliteal lesions were most fre-
quently treated with either PTA alone,
a drug-coated balloon (DCB) or a self-
expanding nitinol stent, all with rela-
tively similar frequencies (. Fig. 3). This
distribution reﬂects the uncertainty in
the various guidelines, recommenda-
tions of which range from the wide
propagation of primary stent angio-
plasty with nitinol stents, to preference
of balloon angioplasty with secondary
stenting (bail out) [14]. At the present
time a general recommendation does
not exist. This was also demonstrated
in a Cochrane review by Chowdhury
et al. [15]. These authors addressed
the question of whether implantation
of uncoated metal stents improved the
vessel patency in symptomatic PAOD
patients with lesions of the superﬁcial
femoral artery, in comparison to PTA.
The analysis of a total of 11 studies (1387
patients) demonstrated a signiﬁcant im-
provement in patency rate (determined
by angiography) at 6 months following
intervention for PTA + stent versus PTA
alone (odds ratio 2.9); however, this
advantage could not longer be observed
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after 12 months. Following this time,
no diﬀerences in walking distance (mea-
sured on a treadmill) or ankle brachial
index (ABI) could be measured. The
same was true for the quality of life.
The data support the recommendations
of the National Institute for Health and
Care Excellence (NICE) [16], which ad-
vise physicians to exercise restraint in
the placement of stents. Jens et al. [17]
came to a similar conclusion in their
systematic review and meta-analysis,
where they name PTA as the method of
choice for above the knee endovascular
interventions in patients with IC, with
optional stenting (bail out) in cases of
inadequate balloon angioplasty. The lat-
est systematic review presented yet more
new recommendations to the National
Health Service (NHS) of the UK, this
time from an economic standpoint [18].
According to this analysis, drug-coated
balloons (DCB) and drug-eluting stents
(DES) provide the greatest clinical and
economic beneﬁts in the endovascu-
lar treatment of suprapopliteal lesions
compared to PTA with uncoated bal-
loons and/or PTA with bare metal stents
(BMS). In infrapopliteal lesions, the vari-
eties of endovascular techniques used in
the PSI study were of minor importance:
PTA alone was predominantly favored
(n = 743), with DCB being implemented
in signiﬁcantly fewer cases (n = 153).
This is in agreement with the current
guideline recommendations. Whether
this approach will endure, amongst nu-
merous other technical possibilities, is
yet to be determined.
The original aim of the PSI study was
to use data to describe the current or
initial situation, which would serve as
a baseline and on future reinvestigation
allow researchers to observe trends in
treatment strategies. Furthermore, it will
be possible to determine how quickly re-
sults of (randomized) studies canandwill
be implemented in actual clinical prac-
tice, also from an economic perspective.
The vast multitude of devices and pro-
cedures employable for such treatments,
even when some are only rarely imple-
mented (. Fig. 3), highlights the need for
further clariﬁcation.
We would like to express our sin-
cere gratitude for the encouraging com-
mitment of the participating centers in
the documentation and reporting of data
from all cases. In 2 years time we plan
on revisiting this investigation in order
to further discuss and review the trends
discussed in this article.
Conclusions for practice
4 In the PSI study 60.1 % of the per-
cutaneous endovascular procedures
in vascular centers run by a vascular
surgeon were performed by vascular
surgeons themselves, 32.8 % by ra-
diologists and 6.9 % by angiologists.
This emphasizes the importance
of cooperation in the treatment of
vascular patients.
4 Patients with intermittent claudi-
cation and critical limb ischemia
signiﬁcantly diﬀered in terms of risk
factors, particularly with respect to
chronic renal disease, diabetes mel-
litus and cardiac risk factors. Of the
patients categorized as PAOD stage II,
41.3 % presentedwith 3 patent crural
vessels compared with only 10.8 % of
patients in stage IV.
4 For suprapopliteal lesions, self-
expanding bare-metal stents (nitinol)
were used in preference to PTA with
uncoated and DCB. Standard PTA, on
the other hand, was themost popular
technique for infrapopliteal lesions.
4 With respect to serious complications
that can arise during intervention,
percutaneous endovascular treat-
ment of intermittent claudication is
considered to be a safe procedure
(serious complications in less than
1% and no deaths).
4 Only 4.5 % of all treatments were
performed under outpatient/day
surgery conditions. Of patients
with PAOD II, however, only 31.9 %
remained in hospital overnight.
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